z-logo
Premium
Prevalence of hypouricaemia and SLC22A12 mutations in healthy Korean subjects
Author(s) -
LEE JOO HOON,
CHOI HYUN JIN,
LEE BEOM HEE,
KANG HEE KYUNG,
CHIN HO JUN,
YOON HYUNG JIN,
HA IL SOO,
KIM SUHNGGWON,
CHOI YONG,
CHEONG HAE IL
Publication year - 2008
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/j.1440-1797.2008.01029.x
Subject(s) - medicine , mutation , pediatrics , genetics , gene , biology
SUMMARY: Aim:  Mutations in the SLC22A12 gene, which encodes a uric acid transporter, URAT1, are associated with renal hypouricaemia. This study was designed to measure serum uric acid (Sua) levels and allele frequencies of two common mutations in SLC22A12 , W258X and R90H, in healthy Korean subjects. Methods:  A total of 909 unrelated Korean adults (male : female, 1:1.23; mean age, 48.4 ± 11.0 years) were recruited among those who had taken a routine health check‐up in a health centre in 2003. None of them had hypertension, diabetes mellitus, kidney diseases or liver diseases. Genotyping for W258X and R90H was performed using the TaqMan method. Results:  The prevalences of hyperuricaemia (Sua levels, >416 µmol/L) and hypouricaemia (Sua levels, <178 µmol/L) were 4.6% and 3.3%, respectively. A marked male preponderance in the hyperuricaemic group was noted, and the men revealed higher Sua than the women. The Sua showed a positive correlation with serum creatinine level and blood pressure. In the hypouricaemic group, the allele frequencies of W258X and R90H were 11.7% and 6.7%, respectively, and the proportion of subjects with one or both of the mutant alleles was 33.3%. Hyperuricaemic subjects never had either mutation. Conclusion:  The W258X and/or R90H mutations in the SLC22A12 gene are one of the major factors responsible for hypouricaemia, and one‐third of the hypouricaemic subjects had one or both of the mutant alleles.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here